We report a case of nivolumab-induced lichen planus (LP) reactivation that was previously in remission following chemotherapy for non-small-cell lung cancer (NSCLC). Chemotherapy-induced immunosuppression allowed for complete resolution of the patient’s pre-existing LP, a T-cell mediated autoimmune process. When the patient was switched to nivolumab immunotherapy owing to progression of NSCLC, PD-1 inhibition led to an overwhelming T-cell response that seemed to have provoked a severe LP reactivation. Although lichenoid reactions have been reported with nivolumab, to our knowledge, this is the first reported case of nivolumab monotherapy causing LP reactivation in a patient with a strong personal and family history of the disease that was previously in remission after chemotherapy.
CITATION STYLE
Maarouf, M., Alexander, C., & Shi, V. Y. (2018). Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature. Dermatology Online Journal, 24(1). https://doi.org/10.5070/d3241037930
Mendeley helps you to discover research relevant for your work.